Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konstanze Döhner

Showing results (1-10 of 276) with videos related to

Pageof 28
Sort By:
Haematologica|July 2, 2008
Molecular characterization of acute myeloid leukemiaKonstanze Döhner, Hartmut Döhner
Seminars in Oncology|August 12, 2008
Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogeneticsVerena Gaidzik, Konstanze Döhner
Hematology. American Society of Hematology. Education Program|February 20, 2015
Intermediate-risk acute myeloid leukemia therapy: current and futureKonstanze Döhner, Peter Paschka
Hematology. American Society of Hematology. Education Program|December 10, 2013
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Peter Paschka, Konstanze Döhner
Current Opinion in Hematology|May 27, 2009
Impact of new prognostic markers in treatment decisions in acute myeloid leukemiaRichard F Schlenk, Konstanze Döhner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysLars Bullinger, Konstanze Döhner, Hartmut Döhner
Hemasphere|July 11, 2020
EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position PaperElizabeth Macintyre, John Gribben, Konstanze Döhner
Seminars in Oncology|August 12, 2008
Acute myeloid leukemia. IntroductionClara D Bloomfield, Guido Marcucci, Konstanze Döhner, et al.
Experimental Hematology|December 21, 2010
TET genes: new players in DNA demethylation and important determinants for stemnessFabian Mohr, Konstanze Döhner, Christian Buske, et al.
Expert Opinion on Drug Safety|June 28, 2021
A review of hydroxyurea-related cutaneous adverse eventsMartin Griesshammer, Kai Wille, Parvis Sadjadian, et al.
Pageof 28

Showing results (1-10 of 276) with videos related to

Sort By:
Pageof 28
Haematologica|July 2, 2008
Molecular characterization of acute myeloid leukemiaKonstanze Döhner, Hartmut Döhner
Seminars in Oncology|August 12, 2008
Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogeneticsVerena Gaidzik, Konstanze Döhner
Hematology. American Society of Hematology. Education Program|February 20, 2015
Intermediate-risk acute myeloid leukemia therapy: current and futureKonstanze Döhner, Peter Paschka
Hematology. American Society of Hematology. Education Program|December 10, 2013
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Peter Paschka, Konstanze Döhner
Current Opinion in Hematology|May 27, 2009
Impact of new prognostic markers in treatment decisions in acute myeloid leukemiaRichard F Schlenk, Konstanze Döhner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysLars Bullinger, Konstanze Döhner, Hartmut Döhner
Hemasphere|July 11, 2020
EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position PaperElizabeth Macintyre, John Gribben, Konstanze Döhner
Seminars in Oncology|August 12, 2008
Acute myeloid leukemia. IntroductionClara D Bloomfield, Guido Marcucci, Konstanze Döhner, et al.
Experimental Hematology|December 21, 2010
TET genes: new players in DNA demethylation and important determinants for stemnessFabian Mohr, Konstanze Döhner, Christian Buske, et al.
Expert Opinion on Drug Safety|June 28, 2021
A review of hydroxyurea-related cutaneous adverse eventsMartin Griesshammer, Kai Wille, Parvis Sadjadian, et al.
Pageof 28